M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash PharmaphorumZymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.Read full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaphorum Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year. Read full story Post navigation Previous: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefitNext: UK partners with Eli Lilly on obesity plan Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026